Rapamycin, an mTORC1 inhibitor, has proven its efficacy to eradicate LICs in PTEN-null preclinical models of murine and human T-ALL, when combined with either the aurora kinase inhibitor, VX-680, or the c-Myc inhibitor, JQ1 [47]. The gene discussed is MYC; the disease is acute lymphoblastic leukemia.